دورية أكاديمية
Identification and surveillance of rare relapse-initiating stem cells during complete remission post-transplantation.
| العنوان: | Identification and surveillance of rare relapse-initiating stem cells during complete remission post-transplantation. |
|---|---|
| المؤلفون: | Dimitriou, Marios, Mortera-Blanco, Teresa, Tobiasson, Magnus, Mazzi, Stefania, Lehander, Madeleine, Högstrand, Kari, Karimi, Mohsen, Walldin, Gunilla, Jansson, Monika, Vonlanthen, Sofie, Ljungman, Per, Langemeijer, Saskia M C, Yoshizato, Tetsuichi, Hellstrom-Lindberg, Eva S, Woll, Petter S, Jacobsen, Sten Eirik W |
| المصدر: | Articles, Abstracts, and Reports |
| بيانات النشر: | Providence Digital Commons |
| سنة النشر: | 2023 |
| المجموعة: | Providence St. Joseph Health Digital Commons |
| مصطلحات موضوعية: | washington, swedish, swedish neuro, Hematology, Neurosciences, Oncology |
| الوصف: | Relapse following complete remission (CR) remains the main cause of mortality after allogeneic stem cell transplantation for hematological malignancies and therefore improved biomarkers for early prediction of relapse remains a critical goal towards development and assessment of preemptive relapse treatment. Since the significance of cancer stem cells as a source of relapses remains unclear, we investigated whether mutational screening for persistence of rare cancer stem cells would enhance measurable residual disease (MRD) and early relapse-prediction post-transplantation. In a retrospective study of relapse patients and continuous-CR patients with myelodysplastic syndromes and related myeloid malignancies, combined flow cytometric cell sorting and mutational screening for persistence of rare relapse-initiating stem cells was performed in bone marrow at multiple CR time points post-transplantation. In 25 CR samples from 15 patients that later relapsed, only 9 samples were MRD-positive in mononuclear cells (MNCs) whereas flowcytometric sorted hematopoietic stem and progenitor cells (HSPCs) were MRD-positive in all samples, and always with a higher variant allele frequency than in MNCs (mean 97-fold). MRD-positivity in HSPCs preceded MNCs in multiple sequential samples, in some cases preceding relapse by more than 2 years. In distinction, in 13 patients in long-term continuous-CR, HSPCs remained MRD-negative. Enhanced MRD-sensitivity was also observed in total CD34+ cells, but HSPCs were always more clonally involved (mean 8-fold).In conclusion, identification of relapse-initiating cancer stem cells and mutational MRD-screening for their persistence consistently enhances MRD-sensitivity and earlier prediction of relapse after allogeneic stem cell transplantation. |
| نوع الوثيقة: | text |
| اللغة: | unknown |
| العلاقة: | https://digitalcommons.providence.org/publications/8192Test; https://pubmed.ncbi.nlm.nih.gov/38096358Test |
| الإتاحة: | https://digitalcommons.providence.org/publications/8192Test https://pubmed.ncbi.nlm.nih.gov/38096358Test |
| رقم الانضمام: | edsbas.6F3547A4 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |